# Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care

> **NCT06832722** · PHASE1,PHASE2 · RECRUITING · sponsor: **4TEEN4 Pharmaceuticals GmbH** · enrollment: 130 (estimated)

## Conditions studied

- Shock, Cardiogenic

## Interventions

- **DRUG:** AK1967 (Invobenitug also known as Procizumab)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06832722
- **Lead sponsor:** 4TEEN4 Pharmaceuticals GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-13
- **Primary completion:** 2026-11-30
- **Final completion:** 2026-12-01
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06832722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06832722, "Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06832722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*